



IMRICOR DIAGNOSTIC CATHETER RECEIVES CE MARK APPROVAL TO SELL INTO EUROPE

Highlights:

- **Vision-MR Diagnostic Catheter approved for sale in EU**
- **Manufacturing of the Vision-MR Diagnostic Catheter to begin in April**
- **Vision-MR Diagnostic Catheter is a lower-cost catheter, improving margins for each procedure**

6 March 2024 – Melbourne, Australia (**5 March 2024** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)** is pleased to announce that the Vision-MR Diagnostic Catheter has received CE mark certification under the new European Union Medical Device Regulations (EU MDR).

Currently, Imricor customers purchase a kit of two Vision-MR Ablation Catheters for each atrial flutter procedure. One ablation catheter is used for ablating, and one is used as a diagnostic (reference) catheter. The kit is sold at a price reflecting what an ablation catheter plus diagnostic catheter would cost.

The lower cost Vision-MR Diagnostic Catheter will replace the second ablation catheter in the kit, thereby improving margins for each procedure. The Company estimates the cost to manufacture the Vision-MR Diagnostic Catheter is approximately 35% less than manufacturing the Vision-MR Ablation Catheter. Manufacturing of the Vision-MR Diagnostic Catheter will begin in April.

Importantly, the Vision-MR Diagnostic Catheter is the first Imricor device to be approved under the new EU MDR regime. Significant work has been done over the past four years to adapt Imricor's Quality Management System (QMS) to comply with the new stricter regulations. The QMS is now certified and can be leveraged as other Imricor products receive certification under the EU MDR regulations.

Imricor's Chair and CEO, Steve Wedan, commented: "We are excited to release the Vision-MR Diagnostic Catheter into the clinical market, at which time we will realise immediate margin improvements.

"This was a huge effort, due to the new Medical Device Regulations in Europe, and our diagnostic catheter's CE mark certification is positive validation of years of work across all functions, led by our world-class Quality and Regulatory team. With this certification, the foundation of our quality system has proven itself solid under EU MDR, and this foundation will be leveraged as the rest of our devices subsequently go through the new European regulatory process."

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

For personal use only



Media and Investor Relations Contact:

Simon Hinsley
simon@nwrcommunications.com.au
+61 401 909 653

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out real-time iCMR cardiac ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also pursuing the required regulatory approvals to place its key products on the market in Australia, the U.S., and the Middle East.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not



place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only

